Naslov
Opinion on an Application for Authorisation for Chromium trioxide use: Functional Chrome Plating

Autori
Committee for Risk Assessment (RAC), Committee for Socio-economic Analysis (SEAC), Rapporteurs: Varnai, Veda Marija ; Tobiassen, Lea Stine ; Csergő, Robert ; Narros, Adolfo

Izvornik
ECHA/RAC/SEAC: Opinion N° AFA-O-0000006522-78-02/F, Helsinki

Vrsta, podvrsta
Ostale vrste radova, ekspertiza

Godina
2016

Ključne riječi
risk assessment, REACH, authorisation, chromium trioxide, functional chrome plating, carcinogenicity, occupational exposure, general population

Sažetak
The Committee for Risk Assessment (RAC) and the Committee for Socio-economic Analysis (SEAC) evaluated the proposal for authorisation submitted by CROMOMED S.A., CRONOR S.A., Cromo Europa S.A., CHROMATLANTIQUE INDUSTRIEL S.A. and VILA ELECTROQUÍMICA S.A., in line with REACH Regulation. The applicants use chromium trioxide for functional (hard) chrome electroplating of a large variety of metal articles and components. RAC assessed the risk of chromium trioxide-related carcinogenicity in exposed workers and general population exposed via the envinronment, taking into account the appropriateness and effectiveness of the risk management measures as described in the application and the risks arising from potential alternatives. RAC confirmed that it is not possible to determine a DNEL for the carcinogenic properties of the substance in accordance with Annex I of the REACH Regulation, that there appear not to be any suitable alternatives that further reduce the risk, and that the operational conditions and risk management measures described in the application do not limit the risk ; however, the suggested conditions and monitoring arrangements are expected to improve the situation. SEAC assessed the socio-economic factors and the availability, suitability and technical and economic feasibility of alternatives associated with the use of chromium trioxide as described in the application. SEAC confirmed that there appear not to be suitable alternatives in terms of their technical and economic feasibility for the applicant, and did not raise any reservations that would change the validity of the applicant’s conclusion that overall benefits of the use outweigh the risk to human health, whilst taking account of any uncertainties in the assessment, provided that the suggested conditions and monitoring arrangements are adhered to. The duration of the review period for the use is recommended to be 7 years.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA